Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changzhou
Clinical trial register · China

Clinical Trials in Changzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 5586 Shanghai 3885 Guangzhou 3356 Hangzhou 1825 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC21 AstraZeneca14 Eli Lilly and Company12 The First People's Hospital of Changzhou5 The First Affiliated Hospital with Nanjing Medical University5 Changzhou No.2 People's Hospital5 Novo Nordisk A/S3 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School3 Nanjing Medical University3 Hoffmann-La Roche2 Takeda2 Daiichi Sankyo2 Ausper Biopharma Co., Ltd.2 Peking Union Medical College Hospital1 Xi Shan Wang1 BeOne Medicines1 Inmunotek S.L.1 Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.1 Xian-Janssen Pharmaceutical Ltd.1 Shanghai Best-Link Bioscience, LLC1 Wu Jun1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 Tianjin Medical University General Hospital1 Hua Jiang1 Alexion Pharmaceuticals, Inc.1 Hong Kong Metropolitan University1 Biotheus Inc.1 Jiangsu Cancer Institute & Hospital1 InnoCare Pharma Inc.1 UCB Biopharma SRL1 WEI XU1 NewAmsterdam Pharma1 Shanghai Tong Ren Hospital1 Sinovac Biotech Co., Ltd1 Evopoint Biosciences Inc.1 Sanofi1 Beijing 302 Hospital1 ShanShan Li1 Novartis Pharmaceuticals1 Bristol-Myers Squibb1 Boehringer Ingelheim1 The First Affiliated Hospital of Soochow University1 Yun Ye1 Jazz Pharmaceuticals1 China Academy of Chinese Medical Sciences1 Fudan University1 National Research Institute for Family Planning, China1 Nanjing IASO Biotechnology Co., Ltd.1 GlaxoSmithKline1 Shanghai Henlius Biotech1 Xuanwu Hospital, Beijing1 Suzhou Hengruihongyuan Medical Technology Co. LTD1 RemeGen Co., Ltd.1 Cai gaojun, MD1 Celgene1 AbbVie1 Amgen1 Dizal Pharmaceuticals1
Site location
Beijing5586 Shanghai3885 Guangzhou3356 Hangzhou1825 Wuhan1342 Chengdu1310 Nanjing1213 Changsha1159 Chongqing1081 Fuzhou1043 Tianjin937 Zhengzhou930 Hefei901 Jinan788 Changchun640 Shenzhen582 Harbin549 Nanchang445 Xi'an442 Nanning439 Suzhou427 Shenyang407 Xiamen392 Shijiazhuang348 Lanzhou272 Bengbu218 Wenzhou189 Kunming187 Guiyang182 Qingdao171 Luoyang156 Ningbo152 Taiyuan148 Foshan144 Dalian135 Xuzhou134 Haikou124 Changzhou124 Dongguan106 Shantou101 Nantong99 Hong Kong98 Wuhu92 Wuxi84 Huizhou83 Baoding83 Anyang83 Baotou82 Zhuhai79 Guangdong76 Xi’an71 Liuzhou70 Cangzhou63 Zhongshan60 Hohhot59 Ganzhou57 Xinxiang57 Taizhou55 Yangzhou55 Jiangmen54 Guilin54 Ürümqi52 Guanzhou51 Yiwu50 Zhanjiang48 Zhejiang47 Yinchuan47 Linyi47 Meizhou46 Fuyang46 Nanyang45 Zunyi45 Zhangzhou44 Quanzhou43 Jinhua43 Hanzhou42 Changde42 Lishui42 Huzhou41 Huai'an39 Langfang38 Jining37 Jiaxing37 Fujian36 Tangshan35 Jilin City34 Xiangyang32 Hunan31 Xining31 Henan31 Binzhou30 Daqing30 Kaifeng29 Shandong28 Yantai28 Changzhi28 Chifeng28 Yichang27 Hengyang27 Chengde27 Xingtai26 Sichuan25 Jingzhou25 Xianyang24 Hubei24 Weifang23 Mianyang23 Shiyan23 Wuzhou22 Hebei22 Haerbin21 Luzhou21 Lianyungang21 Wuwei21 Jiamusi20 Shaoguan19 Nanchong19 Deyang19 Bozhou18 Zhenjiang18 Liaocheng18 Anqing18 Chenzhou18 Putian18 Shanxi18 Yancheng18 Shaoxing17 Handan16 Qingyuan16 Quzhou16 Zibo15 Yulin15 Qinhuangdao15 Shangqiu15 Chizhou15 Guangxi14 Xian14 Maoming14 Pingxiang14 Luoyang Shi14 Haidian13 Guizhou13 Heilongjiang13 Zhenzhou12 Xiangtan12 Dongyang12 Jiaozuo12 Shengyang12 Ha’erbin12 Linfen11 Nanjin11 Kunshan11 Chaoyang11 Huaian11 Yan’an11 Ma’anshan11 Suqian11 Beijin11 Guandong11 Huanggang10 Jiujiang10 Qionghai10 Zhuzhou10 Ankang10 Jieyang10 Longyan10 Heyuan10 Tianjing10 Baise City10 Guigang9 Tongling9 Weinan9 Chuzhou9 Hanzhong9 Neijiang9 Liupanshui8 Heze8 Yueyang8 Zigong8 Jiangxi8 Linhai8 Zhaoqing8 Huaihua8 Shaoyang8 Tai’an8 Qinzhou8 Zhoukou8 Dezhou7 Dongying7 Xuchang7 Hengshui7 Shenzhen Shi7 Ch’ang-ch’un7 Zhangjiakou7 Anhui7 Jinjiang7 Sanming7 Fuzhou Fujian7 Hainan7 Cheng Du Shi7 Lu'an7 Yibin7 Sanya7 Dali7 Huainan7 Baoji7 Xicheng7 Kashgar6 Puyang6 Huangshi6 Suining6 Jinzhou6 Meihekou6 Luohe6 Xuancheng6 Chaoyang District6 Zhoushan6 Kaili6 China6 Yuncheng6 Shanghai Shi6 Naning6 Xuhui6 Dazhou6 Macao5 Enshi5 Anshan5 Yuzhong5 Yixing5 Datong5 Yuhuan5 Dongcheng5 Panjin5 Sanmenxia5 Qianjiang5 Shihezi5 Wanzhou5 Changping5 Jiazhuang5 Mudanjiang5 Haidian District5 Tongliao5 Lanxi5 Bijie5 Zhumadian5 Wenling4 Jiangsu4 Weihai4 Xianning4 Taian4 Benxi4 Qinghai4 Huangshan City4 Ya'an4 Ningde4 Hezhou4 Suzhu4 Jiangyin4 Ji'nan4 Qiqihar4 Chaohu4 Pudong4 Changshu4 Jingdezhen4 Yongzhou4 Multiple Locations4 Jiuquan4 Huangpu4 Gaozhou4 Anning4 Chendu4 Yunnan3 Aksu3 Yanan3 Beijingcun3 Shanwei3 Shunde3 Zhujiang3 Changsha Shi3 Rizhao3 Shapingba3 Bishan3 Dongwan3 Anshun3 Minhang District3 Gansu3 Binhai3 Huaibei3 Chongqicun3 Dengzhou3 Yangpu3 Shang'ai3 Loudi3 Leshan3 Ji’an3 Xingyi3 Guankou3 Fushun3 Fuxin3 Guangdong Province3 Hebi3 Yangjiang3 Neimeng3 Jiyuan3 Zhangjiang3 Lhasa3 Weihui3 Beihai3 Xinjiang3 Yunfu3 Linqing2 Maanshan2 Meishan2 Liangyugang2 Ninghai2 Fuling2 Hechuan2 Yichang Shi2 Guiping2 Karamay2 Taipei2 Ningxia2 Xigazê2 Inner Mongolia2 Pingdingshan2 Yichun2 Herbin2 Gongshu District2 Chongqi2 Tongzhou2 Meicheng2 Tongren2 Baotou Shi2 Xuhui District2 Shatin2 Changzhou Shi2 Hechi2 Jishou2 Huayuan2 Dangyang2 Yixingcun2 Dandong2 Zaozhuang2 Yueqing2 Chibi2 Jingjiang2 Suizhou2 Xiaogan2 Jing’an2 Haozhou2 Dingxi2 Changle2 Macau2 Panlong2 Guli2 Many Locations2 Yisa2 Shanhai2 Lincang2 Xicheng District2 Fengtai2 Jincheng2 Rui’an2 Yiyang2 Xinyang2 Danyang2 Qiandongnan Miao and Dong Autonomous Prefecture2 Qiannan2 Jiaxin2 Xiantao2 Tianshui2 Jinzhong2 Guangyuan2 Nan'ning2 Taiwan2 Qujing2 Taihe Chengguanzhen2 Anxi2 Changlexi2 Hetian1 Yangcheng1 Chengdoucun1 Feicheng1 Jingmen1 Chengdu, Sichuan1 Chancheng District1 Liwan District1 North Street1 Nanshan District1 Luoyan1 Hami1 Liu‘an1 Xianmencun1 Zhenngzhou1 Xichengqu Beijing1 Beijing Sheng1 Gunan1 Jiangjin1 Wulong1 Sanhe1 Ruyang1 Qidong1 Xiangya1 Tongji1 Wujin District1 Guangong Apt/Yuncheng1 Chaozhou1 Jimsar1 Luopu1 Yining1 Tainan1 Taoyuan1 Changchuan1 Guangzhusi1 Zhuozhou1 Fyzhou1 Qingyang1 Lingchuan1 Xing’an1 Daming1 Dingxing1 Zhengding1 Wenquan1 Shangluo1 Ji'an1 Dexing1 Wanzai1 Linxia1 Siping1 Wuhai1 Dongguan Shi1 Pinggu1 Xi'an, China1 Chongli1 Beijing, China1 Beijeing1 Deyang Shi1 Foshan Shi1 Taishing1 Xiameng1 Tongchuan1 Hexi District, Tianjin1 Daping1 Pu'er1 Ezhou1 Chengxiang1 Zheng'zhou1 Heihe1 Lianyuan1 Yongji1 Hongcun1 XiAn1 Zhangjiagang1 Nayong1 Yuzhong District1 Shenyany1 Hengzhou1 Duyun1 Ordos1 Chian1 Guanghzou1 Heifei1 Maoming Shi1 Tiyuan1 Nanzhang Chengguanzhen1 Chongzuo1 Laibin1 Pinghu1 Guangxi Zhuang Autonomous Region1 Fulingqu1 Siming1 Changning1 Lingbao1 Fengcheng1 Beijjing1 Zhangye1 Yizheng1 Junxian1 Pingdu1 Zouping1 Huozhou1 Jiexiu1 Hegang1 Shuangyashan1 Suihua1 Louxing District1 Guang’an1 Dongfang1 Minhang1 Shancheng1 Yangzhou SHI1 Cangzhou Shi1 Chongging1 Linquan County1 Guangdong Province Guangzhou City1 Fenyang1 Jiayuguan1 Liangshan1 Ziyang1 Shenzhencun1 Zhaotong1 Yingtan1 Xiangshan1 Liaoyou1 Taihe1 Zhangping1 Longzhou1 Bingjie1 Gannan1 Hexi District1 Jixi1 Yangchun1 Sanjiaocheng1 Chuangchun1 Daozhen Klau and Hmong Autonomous County in Zun'yi1 Qiandongnan Miao and Dong Autonomous Region1 Jina1 Chang’an1 Cili1 Lanshan1 Leiyang1 Pingjiang1 Yangzhong1 Tianmen1 XI 'an City, Shaanxi Province1 Laizhou1 Qinhuangdao Shi1 Linyi Shi1 Linping1 Qingzhen1 Ningxiang1 Jianli City, Jingzhou City1 Jingxi1 Tengzhou Town1 Xiangyang City, Hubei Province1 Changcun1 Chongoing1 Zunhua1 Mengzhou1 Nanle1 Pizhou1 Changshang1 Yanji1 Gu'ang'zhou1 Ulanhot1 Jihan1 Hubei Sheng1 Wenshan Zhuang and Miao Autonomous Prefecture1 Anhui Sheng1 Zhongshan Town1 Yushu1 Sichuan Chengdu1 Jiangse1 Binzhou Shi1 Changhua1 Wuhang1 Gengma County1 Xian City1 Baiyin1 Xinle1 Yunlin1 Bayan Nur1 Anning, Yunnan - South Region1 Beijing, Beijing1 Cangzhou, Hebei - North Region1 Caoxian County, Shandong Province1 Changzhou, Jiangsu Province1 Chengdu, Sichuan Province1 Chongqing, Chongqing1 Chongqing, Sichuan Province1 Wu’an1 Fuding1 Zhuji1 Kaiping1 Heping1 GuiZhou1 HuBei1 HuNan1 Baoshan1 Tanjing1 Haizhu1 Shijia Zhuang1 Jiancheng1 Fuqing1 Nanping1 Tanjin1 Jiading1 Shushan1 Lanfang1 Chuxiong1 Puer1 Wenshan1 Hengshui Shi1 Dazhu1 Dingzhou1 Shang’ai1 Feixian1 Gulin1 Hanyang1 Wannan1 Beiliu1 Guidong1 Xizang1 Gongyi1 Fu'zhou1 Wuha1 Tacheng1 Longgang1 Jinghong1 Zhengjiang1 Puning1 Hongkou1 Heifi1 Changshan1 Najing1 Gui'lin1 Hshijiazhuang1 Wuhou District1 Changshashi1 Shanhu1 Xiangyun1 Xinzheng1 Hangzou1 Yongcheng1 Jining Shi1
All 625 locations
Target enrolment
to

Trials with a site in Changzhou

124 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
AstraZeneca
Phase 3
330
Beijing, Bozhou, Cangzhou, Changzhou, Chongqing, Daqing, Ganzhou, Guangzhou
2027-01-04
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Beijing, Chongqing, Guangzhou, Shijiazhuang, Luoyang, Changsha, Changzhou, Nanjing
2026-10-26
Recruiting
Janssen Research & Development, LLC
Phase 2
440
Beijing, Changzhou, Ningbo, Taiyuan
2026-10-05
Not yet open
The First People's Hospital of Changzhou
Phase 1/2
49
Changzhou
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2026-09-01
Recruiting
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Recruiting
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Recruiting
Sinovac Biotech Co., Ltd
Observational
106
Changzhou
2026-08-02
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
DrugsPenpulimab·Cytarabine·Methotrexate·Rituximab
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
Changzhou No.2 People's Hospital
Observational
5,000
Changzhou
2026-07-21
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
39
Changzhou, Nanjing
2026-07-15
Recruiting
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
ShanShan Li
Observational
300
Shenzhen, Huai'an, Suzhou, Xuzhou, Dongying, Shanghai, Changzhou, Jiaozuo
2026-07-02
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
DrugAHB-171
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Not yet open
Shanghai Best-Link Bioscience, LLC
Phase 1
33
Harbin, Zhengzhou, Wuhan, Changzhou, Shenyang, Taizhou, Shanghai
2026-06-16
Not yet open
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Beijing, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou
2026-05-22
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Changzhou, Chongqing, Fuzhou, Guangzhou, Nanjing, Wuhan
2026-04-21
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Not yet open
The First Affiliated Hospital of Soochow University
Phase 3
204
Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing
2026-03-10
Recruiting
Cai gaojun, MD
Not applicable
594
Changzhou
2026-02-24
Not yet open
Objective Vascular Biomarkers as Triage for Depression in Chronic Atrophic Gastritis
NCT07319338Chronic Atrophic Gastritis, Depressive Symptoms, Depression, Gastrointestinal Diseases
China Academy of Chinese Medical Sciences
Observational
520
Beijing, Hengshui, Changzhou
2026-02-01
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
Recruiting
Yun Ye
Observational
600
Changzhou
2025-12-24
Recruiting
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shenzhen, Shijiazhuang, Tianjin
2025-12-11
Recruiting
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
By invitation
Non-Invasive Brain-Computer Interface Combined With Transcranial Electrical Stimulation for Peripheral Facial PalsyStimulation in the Treatment of Peripheral Facial Palsy
NCT07327710Peripheral Facial Palsy, Pulsed Radiofrequency, Brain-Computer Interface, Transcranial Direct Current Stimulation
Nanjing Medical University
Not applicable
30
Changzhou
2025-11-30
Recruiting
Eli Lilly and Company
Phase 2
252
Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang
2025-11-10
Recruiting
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Beijing, Changzhou, Cheng Du Shi, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou
2025-10-01
Recruiting
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
DrugMazdutide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
420
Changsha, Changzhou, Nanjing, Dalian, Shanghai
2025-09-27
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugsBirelentinib·Venetoclax
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
AstraZeneca
Observational
700
Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou, Hangzhou
2025-07-11
Recruiting
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Recruiting
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Recruiting
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Active, closed
Amgen
Phase 4
102
Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong
2025-05-24
Not yet open
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Not yet open
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
Changzhou No.2 People's Hospital
Phase 1
18
Changzhou
2025-05
Recruiting
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, Ürümqi, Beijing, Changsha, Changzhou
2025-04-30
Recruiting
Hua Jiang
Phase 2
30
Changzhou
2025-04-17
Recruiting
Inmunotek S.L.
Phase 3
736
Beijing, Guangzhou, Zhongshan, Xiangya, Changzhou, Qingdao, Shanghai, Tongji
2025-04-02
Not yet open
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
NCT06838520Prostate Cancer (Adenocarcinoma)
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Changzhou, Nanjing, Suzhou, Yangzhou
2025-04-01
Active, closed
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
Recruiting
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Hangzhou, Harbin
2025-03-27
Recruiting
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Active, closed
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
980
Zhengzhou, Changzhou, Nanjing, Suzhou, Xi’an
2025-03-01
Recruiting
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Active, closed
Ausper Biopharma Co., Ltd.
Phase 2
105
Chongqing, Fuzhou, Guangzhou, Changzhou, Zhenjiang, Hangzhou
2024-12-13
Active, closed
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Active, closed
BeOne Medicines
Phase 2
94
Fuzhou, Zhengzhou, Changzhou, Nanjing, Shanghai, Hangzhou
2024-11-14
Recruiting
The First People's Hospital of Changzhou
Phase 3
200
Zhengzhou, Changzhou
2024-11-08
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
2024-10-29
Recruiting
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Recruiting
Changzhou No.2 People's Hospital
Early Phase 1
9
Changzhou
2024-08-30
Active, closed
Tianjin Medical University General Hospital
Phase 2/3
102
Hefei, Lanzhou, Shijiazhuang, Harbin, Zhenzhou, Ordos, Changzhou, Suzhou
2024-07-09
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
140
Guangzhou, Zhuhai, Chengde, Harbin, Changsha, Changzhou, Binzhou, Shanghai
2024-06-27
Active, closed
Hong Kong Metropolitan University
Not applicable
32
Changzhou, Nanjing, Hong Kong
2024-06-01
Recruiting
Changzhou No.2 People's Hospital
Phase 2
198
Changzhou
2024-06-01
Recruiting
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Recruiting
The First People's Hospital of Changzhou
Not applicable
30
Changzhou
2024-05-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Observational
112
Changzhou, Nanjing, Nantong, Taizhou, Yancheng
2024-05-01
By invitation
The First People's Hospital of Changzhou
Not applicable
128
Changzhou
2024-04-11
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Active, closed
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Recruiting
GlaxoSmithKline
Phase 3
864
Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan
2024-03-21
Active, closed
Eli Lilly and Company
Phase 3
17,300
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng, Chongqing
2024-03-05
Recruiting
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Not yet open
Wu Jun
Phase 2
40
Changzhou
2024-02-03
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Active, closed
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Recruiting
Changzhou No.2 People's Hospital
Not applicable
300
Changzhou
2023-12-01
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Active, closed
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Active, closed
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Recruiting
Peking Union Medical College Hospital
Not applicable
2,478
Beijing, Changchun, Changsha, Changzhou, Chengdu, Dalian, Dongying, Guiyang
2023-05-26
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Recruiting
Shanghai Tong Ren Hospital
Phase 2
58
Changzhou, Chengdu, Ch’ang-ch’un, Ha’erbin, Hefei, Jiaxing, Lanzhou, Ningbo
2023-02-20
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
4,500
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2022-12
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Not yet open
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou
2022-01-19
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Active, closed
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Changzhou
2021-04-01
Recruiting
Biotheus Inc.
Phase 1/2
380
Baoji, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing
2021-03-09
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-09-30
Active, closed
Eli Lilly and Company
Phase 3
996
Hefei, Chongqing, Xiamen, Foshan, Guangzhou, Wuhan, Changsha, Changzhou
2020-06-22
Active, closed
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
DrugAcalabrutinib
AstraZeneca
Phase 1/2
105
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Haikou, Hangzhou
2020-04-29
Active, closed
Eli Lilly and Company
Phase 3
261
Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai
2020-02-17
Active, closed
AstraZeneca
Phase 3
155
Beijing, Changchun, Changsha, Changzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2020-01-20
Recruiting
National Research Institute for Family Planning, China
Observational
20,000
Zhongshan, Zhangjiakou, Daqing, Changzhou, Yangzhou, Hohhot, Qingdao, Zaozhuang
2019-06-01
Active, closed
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Recruiting
Xi Shan Wang
Observational
3,060
Shijiazhuang, Harbin, Wuhan, Changsha, Changzhou, Xuzhou, Yangzhou, Anshan
2018-11-02
Active, closed
Eli Lilly and Company
Phase 3
1,058
Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2018-07-18
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2018-04-13
Recruiting
Nanjing Medical University
Observational
10,000
Beijing, Chongqing, Guangzhou, Nanning, Xingyi, Harbin, Changzhou, Suqian
2016-01-01
Active, closed
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Active, closed
The First People's Hospital of Changzhou
Phase 2/3
50
Changzhou
2012-07
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
20,000
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2008-01
Rows per page Showing 1–124 of 124
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/changzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 124 of those studies with a site in Changzhou.

How many clinical trials are recruiting in Changzhou?

66 of the 124 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 14 have not yet opened recruitment, 42 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changzhou), 124 studies
PhaseStudiesRecruitingShare
Phase 3562645.2%
Phase 2221417.7%
Observational171313.7%
Not applicable1279.7%
Phase 2/3614.8%
Phase 1413.2%
Phase 1/2312.4%
Phase 4322.4%
Early Phase 1110.8%

Most active sponsors

Lead sponsors with the most studies (Changzhou)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC217
AstraZeneca147
Eli Lilly and Company127
Changzhou No.2 People's Hospital54
The First Affiliated Hospital with Nanjing Medical University54
The First People's Hospital of Changzhou52
Nanjing Medical University31
Novo Nordisk A/S31
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School33
Ausper Biopharma Co., Ltd.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.